---
title: "CERo Therapeutics | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282893291.md"
datetime: "2026-04-15T20:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282893291.md)
  - [en](https://longbridge.com/en/news/282893291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282893291.md)
---

# CERo Therapeutics | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -22.58.

EBIT: As of FY2025, the actual value is USD -18.47 M.

#### Net Loss and Accumulated Deficit

CERo Therapeutics Holdings, Inc. reported a net loss of - $19.9 million for the year ended December 31, 2025, an increase from - $8.3 million for the year ended December 31, 2024, leading to an accumulated deficit of approximately - $90.8 million as of December 31, 2025.

#### Liquidity

As of December 31, 2025, the company had approximately $1.7 million in cash and cash equivalents and a working capital deficit of approximately - $6.4 million, indicating substantial doubt about its ability to continue as a going concern.

#### Operating Expenses

-   Research and Development (R&D) Expenses increased by 46.6% from $7,079,744 in 2024 to $10,381,944 in 2025.
-   General and Administrative Expenses decreased by 11.4% from $9,118,292 in 2024 to $8,081,205 in 2025.
-   Total Operating Expenses increased by 14.0% from $16,198,036 in 2024 to $18,463,149 in 2025.

#### Loss from Operations

The loss from operations increased by 14.0% from - $16,198,036 in 2024 to - $18,463,149 in 2025.

#### Other Income (Expenses)

-   Gain from settlement of liabilities with vendor was $0 in 2025 compared to $3,339,223 in 2024.
-   Other income (expenses) was $242 in 2025 compared to - $672,378 in 2024.
-   Change in fair value of derivative liabilities and earnout liabilities was $0 in 2025 compared to $5,200,117 in 2024.
-   Share-based inducement expenses were - $863,550 in 2025 compared to $0 in 2024.
-   Write off of deferred offering costs was - $605,419 in 2025 compared to $0 in 2024.
-   Interest income, net was $11,614 in 2025 compared to $0 in 2024.

#### Cash Flow

Net cash used in operating activities was - $16.1 million for the year ended December 31, 2025.

#### Operational Metrics & Clinical Development

-   **Clinical Trial Progress**: CERo Therapeutics Holdings, Inc. initiated a Phase 1 clinical trial for CER-1236 in patients with Acute Myeloid Leukemia (AML) in May 2025, with cell products for four patients successfully manufactured and administered by December 31, 2025, and the trial expanded to include Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).
-   **Regulatory Designations**: CER-1236 received FDA Orphan Drug Designation for AML in July 2025 and FDA Fast Track Designation for AML in September 2025, while an Investigational New Drug Application (IND) for Non-Small Cell Lung Cancer (NSCLC) and ovarian cancer was accepted by the FDA on March 27, 2025.
-   **Employee Headcount**: As of December 31, 2025, the company had eight full-time employees, including two executive officers and six employees in Research and Development.

#### Outlook / Guidance

CERo Therapeutics Holdings, Inc. expects significant expenses and increasing operating losses for the foreseeable future and anticipates initiating a Phase 1 study in NSCLC and ovarian cancer in the first quarter of 2026. The company requires additional funds to maintain operations and continue R&D activities, with no assurance of securing sufficient funding.

### Related Stocks

- [CERO.US](https://longbridge.com/en/quote/CERO.US.md)

## Related News & Research

- [How Scott Bessent used financial engineering to finance the $2 trillion deficit while leaving it untouched—and created a $1.45 trillion shortfall](https://longbridge.com/en/news/295299500.md)
- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [US July deficit tops $432 billion as outlays grow, tariff receipts stay negative](https://longbridge.com/en/news/295696210.md)
- [12:14 ETAs Spinal Muscular Atrophy (SMA) Awareness Month Begins, Cure SMA Spotlights Progress and Persistent Gaps in SMA Care](https://longbridge.com/en/news/295258218.md)
- [Hub Group delays Q2 10-Q filing after 2025 annual report setback](https://longbridge.com/en/news/295525695.md)